Lilly's upcoming mid-stage data puts amylin drug design under spotlight

The structural design of amylin-based therapies is emerging as a critical factor in the competitive landscape. Novo Nordisk's CagriSema, a combination of an amylin analog and a GLP-1 agonist, is expected to be the first such drug to gain approval later this year. Lilly's forthcoming mid-stage trial results will likely influence the ongoing debate over optimal amylin design.